Antonio La Cava

List of Publications by Year in Descending Order

161 papers	9,044 citations	53 h-index	92 g-index
172 ext. papers	10,171 ext. citations	9 avg, IF	6.33 L-index

#	Paper	IF	Citations
161	Nanoparticle-mediated delivery of IL-2 to T follicular helper cells protects BDF1 mice from lupus-like disease. *Rheumatology and Immunology Research*, **2021**, 2, 185-193	0.2	0
160	Systemic lupus erythematosus and coronavirus disease 2019. *Rheumatology and Immunology Research*, **2021**, 2, 15-18	0.2	
159	The pleiotropic roles of leptin in metabolism, immunity, and cancer. *Journal of Experimental Medicine*, **2021**, 218,	16.6	10
158	Nanoparticles Engineered as Artificial Antigen-Presenting Cells Induce Human CD4 and CD8 Tregs That Are Functional in Humanized Mice. *Frontiers in Immunology*, **2021**, 12, 628059	8.4	6
157	Strategies to Use Nanoparticles to Generate CD4 and CD8 Regulatory T Cells for the Treatment of SLE and Other Autoimmune Diseases. *Frontiers in Immunology*, **2021**, 12, 681062	8.4	4
156	Overview of the pathogenesis of systemic lupus erythematosus **2021**, 69-75		1
155	T-cell biology, tolerance, and regulation **2021**, 81-98		
154	Antiphospholipid antibodies and COVID-19. *Autoimmunity Reviews*, **2021**, 20, 102910	13.6	3
153	Serafino Zappacosta: An Enlightened Mentor and Educator. *Frontiers in Immunology*, **2020**, 11, 217	8.4	0
152	DNA vaccine encoding heat shock protein 90 protects from murine lupus. *Arthritis Research and Therapy*, **2020**, 22, 152	5.7	0
151	DNA Vaccination With Hsp70 Protects Against Systemic Lupus Erythematosus in (NZB □NZW)F1 Mice. *Arthritis and Rheumatology*, **2020**, 72, 997-1002	9.5	5
150	Anti-CD2 Antibody-Coated Nanoparticles Containing IL-2 Induce NK Cells That Protect Lupus Mice a TGF-□Dependent Mechanism. *Frontiers in Immunology*, **2020**, 11, 583338	8.4	3
149	The Influence of Diet and Obesity on Gene Expression in SLE. *Genes*, **2019**, 10,	4.2	6
148	Rebalancing Immune Homeostasis to Treat Autoimmune Diseases. *Trends in Immunology*, **2019**, 40, 888-908	14.4	42
147	Human T cell repertoire: what happens in thymus does not stay in thymus. *Journal of Clinical Investigation*, **2019**, 129, 2195-2197	15.9	2
146	Adaptive and Innate Immunoregulatory Cells **2019**, 125-136		0
145	Suppression of Murine Lupus by CD4+ and CD8+ Treg Cells Induced by T Cell-Targeted Nanoparticles Loaded With Interleukin-2 and Transforming Growth Factor □*Arthritis and Rheumatology*, **2019**, 71, 632-640	9.5	29

144	Tregs in SLE: an Update. *Current Rheumatology Reports*, **2018**, 20, 6	4.9	17
143	Brain Ischemia Induces Diversified Neuroantigen-Specific T-Cell Responses That Exacerbate Brain Injury. *Stroke*, **2018**, 49, 1471-1478	6.7	28
142	Organ- and cell-specific immune responses are associated with the outcomes of intracerebral hemorrhage. *FASEB Journal*, **2018**, 32, 220-229	0.9	32
141	IRF1 and BATF: key drivers of type 1 regulatory T-cell differentiation. *Cellular and Molecular Immunology*, **2017**, 14, 652-654	15.4	7
140	Brain Ischemia Suppresses Immunity in the Periphery and Brain via Different Neurogenic Innervations. *Immunity*, **2017**, 46, 474-487	32.3	93
139	Metabolic pressure and the breach of immunological self-tolerance. *Nature Immunology*, **2017**, 18, 1190-1196	19.1	35
138	Leptin in inflammation and autoimmunity. *Cytokine*, **2017**, 98, 51-58	4	137
137	Leptin promotes systemic lupus erythematosus by increasing autoantibody production and inhibiting immune regulation. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 10637-42	11.5	59
136	Role of Metabolism in the Immunobiology of Regulatory T Cells. *Journal of Immunology*, **2016**, 197, 2567-75	5.3	71
135	The Proteomic Landscape of Human Ex Vivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements. *Immunity*, **2016**, 44, 406-21	32.3	148
134	Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation. *Nature Neuroscience*, **2016**, 19, 243-52	25.5	72
133	Adaptive immune regulation in autoimmune diabetes. *Autoimmunity Reviews*, **2016**, 15, 236-41	13.6	16
132	Overview of the Pathogenesis of Systemic Lupus Erythematosus **2016**, 55-62		7
131	Regulatory T Cells in SLE: Biology and Use in Treatment. *Current Rheumatology Reports*, **2016**, 18, 67	4.9	20
130	Putting together the autoimmunity puzzle. *Journal of Clinical Investigation*, **2015**, 125, 2184-6	15.9	5
129	Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. *Nature Immunology*, **2015**, 16, 1174-84	19.1	219
128	Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. *Clinical Immunology*, **2015**, 161, 157-62	9	8
127	Regulatory CD4+ T cells promote B cell anergy in murine lupus. *Journal of Immunology*, **2014**, 192, 4069-73	5.3	17

126	Novel approaches to lupus drug discovery using stem cell therapy. Role of mesenchymal-stem-cell-secreted factors. *Expert Opinion on Drug Discovery*, **2014**, 9, 555-66	6.2	13
125	Regulatory T cell proliferative potential is impaired in human autoimmune disease. *Nature Medicine* , **2014**, 20, 69-74	50.5	159
124	IL-17 promotes murine lupus. *Journal of Immunology*, **2014**, 193, 540-3	5.3	96
123	Genetic deficiency of 2-containing nicotinic receptors attenuates brain injury in ischemic stroke. *Neuroscience*, **2014**, 256, 170-7	3.9	12
122	miR-126, a new modulator of innate immunity. *Cellular and Molecular Immunology*, **2014**, 11, 215-7	15.4	22
121	Leptin enhances availability of apoptotic cell-derived self-antigen in systemic lupus erythematosus. *PLoS ONE*, **2014**, 9, e112826	3.7	21
120	Ischemic neurons recruit natural killer cells that accelerate brain infarction. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 2704-9	11.5	158
119	Epigenetic dysregulation in systemic lupus erythematosus. *Autoimmunity*, **2014**, 47, 215-9	3	23
118	Meta-immunological profiling of children with type 1 diabetes identifies new biomarkers to monitor disease progression. *Diabetes*, **2013**, 62, 2481-91	0.9	17
117	Serum IFN- is abnormally elevated in rheumatoid arthritis patients. *Autoimmunity*, **2013**, 46, 40-3	3	22
116	Leptin promotes lupus T-cell autoimmunity. *Clinical Immunology*, **2013**, 149, 530-3	9	36
115	Targeting the BLyS-APRIL signaling pathway in SLE. *Clinical Immunology*, **2013**, 148, 322-7	9	18
114	Adiponectin: a relevant player in obesity-related colorectal cancer?. *Gut*, **2013**, 62, 483-4	19.2	5
113	Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease. *Journal of Immunology*, **2013**, 190, 5402-10	5.3	45
112	Cutting edge: Leptin-induced ROR expression in CD4+ T cells promotes Th17 responses in systemic lupus erythematosus. *Journal of Immunology*, **2013**, 190, 3054-8	5.3	96
111	Regulatory Cells in SLE **2013**, 104-114		
110	Common variable immunodeficiency: two mutations are better than one. *Journal of Clinical Investigation*, **2013**, 123, 4142-3	15.9	7
109	In vivo veritas, in vitro artificia. *Trends in Molecular Medicine*, **2012**, 18, 439-42	11.5	11

108	Preclinical studies with synthetic peptides in systemic lupus erythematosus. *Frontiers in Bioscience - Landmark*, **2012**, 17, 1940-7	2.8	6
107	Tolerance induced by anti-DNA Ig peptide in (NZB×NZW)F1 lupus mice impinges on the resistance of effector T cells to suppression by regulatory T cells. *Clinical Immunology*, **2012**, 142, 291-5	9	12
106	miRNA in systemic lupus erythematosus. *Clinical Immunology*, **2012**, 144, 26-31	9	61
105	Cutting edge: fasting-induced hypoleptinemia expands functional regulatory T cells in systemic lupus erythematosus. *Journal of Immunology*, **2012**, 188, 2070-3	5.3	53
104	Targeting BLyS in systemic lupus erythematosus. *Recent Patents on Inflammation and Allergy Drug Discovery*, **2012**, 6, 91-6	5.4	1
103	The Effects of Curcumin on Immune Responses. *Current Bioactive Compounds*, **2012**, 8, 142-145	0.9	2
102	Leptin-induced mTOR activation defines a specific molecular and transcriptional signature controlling CD4+ effector T cell responses. *Journal of Immunology*, **2012**, 189, 2941-53	5.3	100
101	Proinflammatory activities of leptin in non-autoimmune conditions. *Inflammation and Allergy: Drug Targets*, **2012**, 11, 298-302		15
100	IL-17 in systemic lupus erythematosus. *Clinical Investigation*, **2012**, 2, 417-421		2
99	Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. *American Journal of Neurodegenerative Disease*, **2012**, 1, 60-74	2.5	48
98	Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. *American Journal of Neurodegenerative Disease*, **2012**, 1, 305-15	2.5	43
97	Natural regulatory T cells in autoimmunity. *Autoimmunity*, **2011**, 44, 33-42	3	61
96	Organ-specific features of natural killer cells. *Nature Reviews Immunology*, **2011**, 11, 658-71	36.5	277
95	Interferon-inducible gene 202b controls CD8(+) T cell-mediated suppression in anti-DNA Ig peptide-treated (NZB×NZW) F1 lupus mice. *Genes and Immunity*, **2011**, 12, 360-9	4.4	13
94	Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. *Annals of Neurology*, **2011**, 69, 721-34	9.4	51
93	Current drugs in systemic lupus erythematosus. *Drug Development Research*, **2011**, 72, 561-572	5.1	0
92	Regulatory immune cell subsets in autoimmunity. *Autoimmunity*, **2011**, 44, 1-2	3	11
91	High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. *Annals of the Rheumatic Diseases*, **2011**, 70, 1619-24	2.4	100

90	Reply to Choubey et al.. *Genes and Immunity*, **2011**, 12, 496-496	4.4	
89	Lupus, the current therapeutic approaches. *Drugs of Today*, **2011**, 47, 289-302	2.5	7
88	Distinct gene signature revealed in white blood cells, CD4(+) and CD8(+) T cells in (NZBx NZW) F1 lupus mice after tolerization with anti-DNA Ig peptide. *Genes and Immunity*, **2010**, 11, 294-309	4.4	12
87	Laboratory medicine in pediatric lupus. *Journal of Pediatric Biochemistry*, **2010**, 01, 045-051		
86	Pro-inflammatory high-density lipoproteins and atherosclerosis are induced in lupus-prone mice by a high-fat diet and leptin. *Lupus*, **2010**, 19, 913-7	2.6	27
85	Curcumin and Immunity. *Current Bioactive Compounds*, **2010**, 6, 156-160	0.9	1
84	Anticytokine therapies in systemic lupus erythematosus. *Immunotherapy*, **2010**, 2, 575-82	3.8	21
83	Blockade of programmed death-1 in young (New Zealand black x New Zealand white)F1 mice promotes the activity of suppressive CD8+ T cells that protect from lupus-like disease. *Journal of Immunology*, **2010**, 185, 6563-71	5.3	31
82	Leptin modulates the survival of autoreactive CD4+ T cells through the nutrient/energy-sensing mammalian target of rapamycin signaling pathway. *Journal of Immunology*, **2010**, 185, 7474-9	5.3	66
81	Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. *Journal of Experimental Medicine*, **2010**, 207, 1907-21	16.6	164
80	Targeting B cells with biologics in systemic lupus erythematosus. *Expert Opinion on Biological Therapy*, **2010**, 10, 1555-61	5.4	18
79	Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. *Arthritis Research and Therapy*, **2010**, 12, R93	5.7	42
78	IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. *Journal of Neuroinflammation*, **2010**, 7, 76	10.1	121
77	Regulatory T cells in obesity: the leptin connection. *Trends in Molecular Medicine*, **2010**, 16, 247-56	11.5	140
76	Leptin as a metabolic link to multiple sclerosis. *Nature Reviews Neurology*, **2010**, 6, 455-61	15	63
75	CD8+ Tregs in lupus, autoimmunity, and beyond. *Autoimmunity Reviews*, **2010**, 9, 560-8	13.6	95
74	Modulation of autoimmunity with artificial peptides. *Autoimmunity Reviews*, **2010**, 10, 18-21	13.6	3
73	Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. *European Journal of Immunology*, **2010**, 40, 1577-89	6.1	72

72	An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. *Immunity*, **2010**, 33, 929-41	32.3	270
71	Leptin signaling: A key pathway in immune responses. *Current Signal Transduction Therapy*, **2009**, 4, 22-30	0.8	38
70	Cutting edge: Regulatory T cells directly suppress B cells in systemic lupus erythematosus. *Journal of Immunology*, **2009**, 183, 1518-22	5.3	150
69	Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB x NZW)F1 lupus mice. *Journal of Immunology*, **2009**, 182, 7415-21	5.3	14
68	Potential for anti-DNA immunoglobulin peptide therapy in systemic lupus erythematosus. *Expert Opinion on Biological Therapy*, **2009**, 9, 201-6	5.4	10
67	Immunotherapy with peptides in systemic lupus erythematosus. *Current Medicinal Chemistry*, **2009**, 16, 1482-8	4.3	3
66	Antibody-based therapies in systemic lupus erythematosus. *Mini-Reviews in Medicinal Chemistry*, **2009**, 9, 829-46	3.2	2
65	The Yin and Yang of CD4(+) regulatory T cells in autoimmunity and cancer. *Current Medicinal Chemistry*, **2009**, 16, 4626-31	4.3	22
64	Cytokines in systemic lupus erythematosus. *Current Molecular Medicine*, **2009**, 9, 242-54	2.5	68
63	Lupus and T cells. *Lupus*, **2009**, 18, 196-201	2.6	40
62	Leptin as clinical target. *Recent Patents on Inflammation and Allergy Drug Discovery*, **2009**, 3, 160-6	5.4	7
61	Mimicking self-antigens with synthetic peptides in systemic autoimmune rheumatic diseases. *Current Clinical Pharmacology*, **2009**, 4, 142-7	2.5	6
60	Leptin in non-autoimmune inflammation. *Inflammation and Allergy: Drug Targets*, **2009**, 8, 285-91		7
59	Natural Tregs and autoimmunity. *Frontiers in Bioscience - Landmark*, **2009**, 14, 333-43	2.8	17
58	The busy life of regulatory T cells in systemic lupus erythematosus. *Discovery Medicine*, **2009**, 8, 13-7	2.5	9
57	Tregs are regulated by cytokines: implications for autoimmunity. *Autoimmunity Reviews*, **2008**, 8, 83-7	13.6	44
56	Cutaneous vasculitis in breast cancer treated with chemotherapy. *Clinical Immunology*, **2008**, 129, 3-9	9	32
55	Regulatory CD4 T cells: sensing the environment. *Trends in Immunology*, **2008**, 29, 12-7	14.4	31

54	IL-21 receptor expression determines the temporal phases of experimental autoimmune encephalomyelitis. *Experimental Neurology*, **2008**, 211, 14-24	5.7	31
53	T-regulatory cells in systemic lupus erythematosus. *Lupus*, **2008**, 17, 421-5	2.6	78
52	pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules. *Journal of Immunology*, **2008**, 180, 2069-80	5.3	57
51	Leptin and Inflammation. *Current Immunology Reviews*, **2008**, 4, 70-79	1.3	204
50	Autoimmunity and celiac disease. *Mini-Reviews in Medicinal Chemistry*, **2008**, 8, 129-34	3.2	10
49	Tuning immune suppression in systemic autoimmunity with self-derived peptides. *Inflammation and Allergy: Drug Targets*, **2008**, 7, 253-9		9
48	New therapies in SLE. *Recent Patents on Inflammation and Allergy Drug Discovery*, **2008**, 2, 11-23	5.4	4
47	IL-21 modulates CD4+ CD25+ regulatory T-cell homeostasis in experimental autoimmune encephalomyelitis. *Scandinavian Journal of Immunology*, **2008**, 67, 37-46	3.4	41
46	CCL2 recruitment of IL-6-producing CD11b+ monocytes to the draining lymph nodes during the initiation of Th17-dependent B cell-mediated autoimmunity. *European Journal of Immunology*, **2008** , 38, 1877-88	6.1	46
45	Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients. *Arthritis and Rheumatism*, **2008**, 58, 2488-97		55
44	Gender-Based Differences in Leptinemia in Healthy Aging, Non-obese Individuals Associate with Increased Marker of Oxidative Stress. *International Journal of Clinical and Experimental Medicine*, **2008**, 1, 305-9		8
43	Protection against renal disease in (NZB x NZW)F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide. *Arthritis and Rheumatism*, **2007**, 56, 1945-53		25
42	Leptin in autoimmunity: many questions, some answers. *Tissue Antigens*, **2007**, 70, 87-95		58
41	Gene vaccination for the induction of immune tolerance. *Annals of the New York Academy of Sciences*, **2007**, 1110, 99-111	6.5	22
40	CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression. *Journal of Immunology*, **2007**, 178, 7649-57	5.3	91
39	Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis. *Current Pharmaceutical Design*, **2007**, 13, 3676-80	3.3	55
38	ApoE-/-Fas-/- C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia. *Journal of Lipid Research*, **2007**, 48, 794-805	6.3	52
37	A key role of leptin in the control of regulatory T cell proliferation. *Immunity*, **2007**, 26, 241-55	32.3	496

36	Natural and adaptive immune cell-based therapies in autoimmunity. *Current Medicinal Chemistry*, **2006**, 13, 1557-66	4.3	4
35	Autoreactive T cells mediate NK cell degeneration in autoimmune disease. *Journal of Immunology*, **2006**, 176, 5247-54	5.3	49
34	CD4+CD25+ Tregs and NKT cells: regulators regulating regulators. *Trends in Immunology*, **2006**, 27, 322-7	14.4	158
33	Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis. *Journal of Clinical Investigation*, **2006**, 116, 447-55	15.9	104
32	Immune responses in obesity models. *Drug Discovery Today: Disease Models*, **2005**, 2, 177-181	1.3	6
31	Cellular and molecular mechanisms of regulation of autoantibody production in lupus. *Annals of the New York Academy of Sciences*, **2005**, 1051, 433-41	6.5	35
30	Manipulation of immune regulation in systemic lupus erythematosus. *Autoimmunity Reviews*, **2005**, 4, 515-9	13.6	28
29	Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. *Journal of Immunology*, **2005**, 174, 2696-701	5.3	115
28	Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors. *Journal of Immunology*, **2005**, 175, 7728-37	5.3	117
27	Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 5150-5	11.5	244
26	Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. *Journal of Immunology*, **2005**, 175, 7898-904	5.3	118
25	Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black x New Zealand White)F1 mice suppress in vitro production of antibodies to DNA. *Journal of Immunology*, **2004**, 173, 3542-8	5.3	93
24	The weight of leptin in immunity. *Nature Reviews Immunology*, **2004**, 4, 371-9	36.5	671
23	Regulation of autoantibody production by multiple mechanisms in immune tolerance. *Autoimmunity Reviews*, **2004**, 3, 615-617	13.6	
22	Unraveling the multiple roles of leptin in inflammation and autoimmunity. *Journal of Molecular Medicine*, **2004**, 82, 4-11	5.5	134
21	Differences between CD8+ T cells in lupus-prone (NZB x NZW) F1 mice and healthy (BALB/c x NZW) F1 mice may influence autoimmunity in the lupus model. *European Journal of Immunology*, **2004**, 34, 2489-99	6.1	28
20	The intricate interface between immune system and metabolism. *Trends in Immunology*, **2004**, 25, 193-200	14.4	168
19	Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. *Journal of Clinical Investigation*, **2003**, 111, 241-50	15.9	94

18	Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. *Journal of Clinical Investigation*, **2003**, 111, 241-250	15.9	231
17	Leptin-based immune intervention: current status and future directions. *Current Opinion in Investigational Drugs*, **2003**, 4, 1327-32		5
16	Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. *Arthritis and Rheumatism*, **2002**, 46, 2721-9		57
15	Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. *Arthritis and Rheumatism*, **2002**, 46, 3015-25		47
14	Leptin accelerates autoimmune diabetes in female NOD mice. *Diabetes*, **2002**, 51, 1356-61	0.9	157
13	Genetic immunization maps T cell (auto)immune responses to self antigens homologous to exogenous proteins. *Autoimmunity*, **2002**, 35, 105-10	3	1
12	Balancing susceptibility to infection and autoimmunity: a role for leptin?. *Trends in Immunology*, **2002**, 23, 182-7	14.4	162
11	H-2D end confers dominant protection from IL-10-mediated acceleration of autoimmune diabetes in the nonobese diabetic mouse. *Journal of Immunology*, **2001**, 167, 1066-71	5.3	3
10	Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis. *Nature Medicine*, **2000**, 6, 693-7	50.5	134
9	A mechanism for IL-10-mediated diabetes in the nonobese diabetic (NOD) mouse: ICAM-1 deficiency blocks accelerated diabetes. *Journal of Immunology*, **2000**, 165, 7330-7	5.3	57
8	Cell-mediated DNA transport between distant inflammatory sites following intradermal DNA immunization in the presence of adjuvant. *Journal of Immunology*, **2000**, 164, 1340-5	5.3	25
7	Genetic immunization for the recovery and purification of recombinant proteins. *Protein Expression and Purification*, **2000**, 18, 361-5	2	2
6	The role of cytokines in autoimmunity. *Current Directions in Autoimmunity*, **1999**, 1, 56-71		9
5	Ontogeny of synonymous T cell populations with specificity for a self MHC epitope mimicked by a bacterial homologoue: an antigen-specific T cell analysis in a non-transgenic system. *European Journal of Immunology*, **1999**, 29, 3826-36	6.1	10
4	B-cell superantigens: molecular and cellular implications. *International Reviews of Immunology*, **1997** , 14, 259-90	4.6	11
3	Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis. *Journal of Clinical Investigation*, **1997**, 100, 658-63	15.9	56
2	Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. *Nature Medicine*, **1995**, 1, 448-52	50.5	153
1	A novel strategy of c-myc oncogene in NK activity regulation not related to the W6/32 MHC class-I epitope. *International Journal of Cancer*, **1994**, 58, 123-8	7.5	5